Systemic Bio Secures $15 Million in Seed Funding for Breakthrough Vascularized Organ Models

Systemic Bio, a pioneering Houston-based company under the 3D Systems umbrella, is thrilled to announce the successful completion of a $15 million funding round aimed at advancing its innovative research in biomedicine. Founded with the vision to revolutionize drug discovery and development, Systemic Bio specializes in creating vascularized organ models crafted from a unique blend of hydrogels and human cells. These advanced organ models possess the potential to mimic human physiological conditions more accurately than traditional models, significantly enhancing the drug screening process for pharmaceutical companies. The funds raised will be instrumental in expanding the company's capabilities to accelerate the development of these vital organ models, allowing researchers and innovators to simulate human responses and interactions in ways that were previously unattainable. As the demand for more predictive preclinical testing solutions grows in an increasingly complex biomedical landscape, Systemic Bio is poised to make a profound impact. The infusion of capital will also support the recruitment of top-tier talent as well as the enhancement of operational facilities, ensuring that the company remains at the forefront of the bioprinting revolution. Systemic Bio's commitment to creating human-compatible models represents a significant leap forward in bioscience, promising not only to streamline drug development timelines and costs but also to foster breakthroughs in patient treatment pathways. The future looks bright as Systemic Bio continues to innovate and reshape the way we understand and develop therapies for human health, stay tuned for more updates on this exciting journey!